• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Atezolizumab and nab-paclitaxel prolong progression-free survival for patients with metastatic triple-negative breast cancer: the IMpassion130 trial

byShani ChibberandDayton McMillan
November 30, 2018
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This randomized controlled trial of women with metastatic triple-negative breast cancer reports that patients who were received atezolizumab with nab-paclitaxel had longer periods of progression-free survival compared to patients who received placebo plus nab-paclitaxel therapy.

2. Rates of adverse events were comparable in both study groups, however it was noted that the incidence of grade 3 or 4 adverse events and immune-related averse events were higher in the atezolizumab plus nab-paclitaxel group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Triple-negative breast cancer is generally regarded as more aggressive and difficult to treat as compared to other subtypes of breast cancer, ultimately leading to poor survival outcomes among patients. The use of immunotherapy with chemotherapy has been investigated in the context of various types of cancers as a way to augment chemotherapy treatment responses. In this current analysis, the IMpassion130 phase three randomized control trial investigated the efficacy of the combined use of atezolizumab, an immunologic agent that binds to programmed death ligand 1 (PDL1) to prevent T-cell suppression with nab-paclitaxel to assess their combined impact on cancer progression-free survival and overall survival as compared to a placebo plus nab-paclitaxel regimen. The safety profiles of each arm were also assessed. Overall, authors found that the combination of atezolizumab with nab-paclitaxel therapy led to longer cancer progression-free survival periods compared to placebo plus nab-paclitaxel. Results were consistent both among their intention-to-treat population and among patients who had PDL1 positive tumors. While preliminary, these results present evidence that immunotherapy could be considered as a possible adjunct therapy for patients with metastatic triple negative breast cancer.

Strengths of this study include evaluation of patient PD-L1 positive patients in addition to additional extensive subgroup analysis. The study lacked author disclosed or observed limitations and lack of non-survival based outcomes, such as quality of life or other patient functional outcomes.

Click to read the study in NEJM

Relevant Reading: Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

RELATED REPORTS

Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

In-Depth [randomized controlled trial]: This phase three, multicenter randomized controlled trial enrolled 902 patients across 41 countries between Jun 2015 to May 2017. Patients were randomized in a 1:1 ratio to either receive atezolizumab plus nab-paclitaxel (n=451) or placebo plus nab-paclitaxel therapy (n=451). Treatment regimens were based off of 28-day cycles; in the absence of disease progression, patients were scheduled to receive at least 6 cycles of chemotherapy.  Atezolizumab or placebo were administered at doses of 840mg on days 1 and 15 of each cycle. Nab-paclitaxel was administered at a dose of 100mg/m2 on days 1, 8 and 15. The primary outcomes of this analysis were to evaluate for progression-free survival and overall survival rates. Survival outcomes were also assessed within a subgroup of patients who were PD-L1 positive (n=369 patients; n=185 atezolizumab with nab-paclitaxel; n=184 placebo with nab-paclitaxel). The median follow-up period was 12.9 months among the total cohort (13.0 months in the atezolizumab-nab-paclitaxel group; 12.5 months in the placebo-nab-paclitaxel group). Progression free survival was noted to be significantly longer in the atezolizumab and nab-paclitaxel group compared to placebo (median survival 7.2 months vs 5.5 months; hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.69 to 0.92; P=0.002). Prolonged progression-free survival was also observed among patients who were in the PD-L1 positive subgroup treated with atezolizumab plus nab-paclitaxel (median progression-free survival 7.5 months vs 5.0 months, HR: 0.62; 95% CI: 0.49 to 0.78, P<0.001). From a safety standpoint, adverse events occurred in 99.3% of patients in the atezolizumab plus nab-paclitaxel group compared to 97.9% in the placebo group. The most common adverse effects included neutropenia, peripheral neuropathy, fatigue and anemia. The rate of grade 3 or 4 adverse events in the atezolizumab therapy group were 48.7% and 42.2% in the placebo group.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Atezolizumab
Previous Post

Fractional-dose vaccination offers long lasting protection against yellow fever

Next Post

The ODYSSEY OUTCOMES trial: Alirocumab associated with reduced ischemic events after acute coronary syndrome

RelatedReports

Complement mutation linked to poor response to eculizumab
Oncology

Overall survival with triplet therapy in BRAF V600 mutation-positive advanced melanoma

December 28, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

October 11, 2022
#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
StudyGraphics

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

October 11, 2022
New genetic link in pulmonary arterial hypertension holds therapeutic promise
Oncology

Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes

July 4, 2022
Next Post
Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

The ODYSSEY OUTCOMES trial: Alirocumab associated with reduced ischemic events after acute coronary syndrome

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Quick Take: Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists

Quick Take: Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options